Pfizer just struck a $5.2 billion deal for an eczema drugmaker
Thomson Reuters
A man enters the employee entrance of the Pfizer World Headquarters building in New York
Anacor already has one approved drug (a topical anti-fungal treatment), but the big draw for Pfizer is a drug called crisaborole to treat eczema, an inflammatory skin condition.
The gel treatment is in the FDA filing process and should be decided on by January 2017, and Pfizer said in a release that it expects peak yearly sales for the drug to hit $2 billion.
In April, the drugmaker's $160 billion megamerger with Allergan was scrapped after the US Treasury released new rules governing so-called tax inversions that undercut the deal's key rationale. Since then, there have been reports that Pfizer is also interested in cancer drugmaker Medivation.
Ultimately, Pfizer (which has both innovative and established sides) is headed for a split-up of the company, which it's expected to give an update on by than the end of 2016. The Anacor acquisition would fit in with that plan by building up the company's inflammation portfolio.
Next Story
I tutor the children of some of Dubai's richest people. One of them paid me $3,000 to do his homework.
John Jacob Astor IV was one of the richest men in the world when he died on the Titanic. Here's a look at his life.
A 13-year-old girl helped unearth an ancient Roman town. She's finally getting credit for it over 90 years later.
Sell-off in Indian stocks continues for the third session
Samsung Galaxy M55 Review — The quintessential Samsung experience
The ageing of nasal tissues may explain why older people are more affected by COVID-19: research
Amitabh Bachchan set to return with season 16 of 'Kaun Banega Crorepati', deets inside
Top 10 places to visit in Manali in 2024
